Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, Simon's 2-stage, proof-of-concept trial. The aim is to evaluate the
efficacy and safety of avelumab with axitinib in patients with persistent or recurrent
cervical cancer following platinum-based chemotherapy. The study hypothesis is that the
combination of avelumab and axitinib can significantly improve the objective response rate
(ORR) with acceptable toxicity compared to traditional chemotherapy.